TY - JOUR
T1 - Stromal ccl5 promotes breast cancer progression by interacting with CCR3 in tumor cells
AU - Yamaguchi, Mio
AU - Takagi, Kiyoshi
AU - Narita, Koki
AU - Miki, Yasuhiro
AU - Onodera, Yoshiaki
AU - Miyashita, Minoru
AU - Sasano, Hironobu
AU - Suzuki, Takashi
N1 - Funding Information:
Funding: This research was funded by JSPS KAKENHI, grant numbers 19K09065 and 19K07410.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/2/2
Y1 - 2021/2/2
N2 - Chemokines secreted from stromal cells have important roles for interactions with carcinoma cells and regulating tumor progression. C-C motif chemokine ligand (CCL) 5 is expressed in various types of stromal cells and associated with tumor progression, interacting with C-C chemo-kine receptor (CCR) 1, 3 and 5 expressed in tumor cells. However, the expression on CCL5 and its receptors have so far not been well-examined in human breast carcinoma tissues. We therefore im-munolocalized CCL5, as well as CCR1, 3 and 5, in 111 human breast carcinoma tissues and correlated them with clinicopathological characteristics. Stromal CCL5 immunoreactivity was signifi-cantly correlated with the aggressive phenotype of breast carcinomas. Importantly, this tendency was observed especially in the CCR3-positive group. Furthermore, the risk of recurrence was sig-nificantly higher in the patients with breast carcinomas positive for CCL5 and CCR3 but negative for CCR1 and CCR5, as compared with other patients. In summary, the CCL5-CCR3 axis might contribute to a worse prognosis in breast cancer patients, and these findings will contribute to a better understanding of the significance of the CCL5/CCRs axis in breast carcinoma microenviron-ment.
AB - Chemokines secreted from stromal cells have important roles for interactions with carcinoma cells and regulating tumor progression. C-C motif chemokine ligand (CCL) 5 is expressed in various types of stromal cells and associated with tumor progression, interacting with C-C chemo-kine receptor (CCR) 1, 3 and 5 expressed in tumor cells. However, the expression on CCL5 and its receptors have so far not been well-examined in human breast carcinoma tissues. We therefore im-munolocalized CCL5, as well as CCR1, 3 and 5, in 111 human breast carcinoma tissues and correlated them with clinicopathological characteristics. Stromal CCL5 immunoreactivity was signifi-cantly correlated with the aggressive phenotype of breast carcinomas. Importantly, this tendency was observed especially in the CCR3-positive group. Furthermore, the risk of recurrence was sig-nificantly higher in the patients with breast carcinomas positive for CCL5 and CCR3 but negative for CCR1 and CCR5, as compared with other patients. In summary, the CCL5-CCR3 axis might contribute to a worse prognosis in breast cancer patients, and these findings will contribute to a better understanding of the significance of the CCL5/CCRs axis in breast carcinoma microenviron-ment.
KW - Breast carcinoma
KW - Chemokine
KW - Immunohistochemistry
KW - Prognosis
KW - Tumor microenviron-ment
UR - http://www.scopus.com/inward/record.url?scp=85100795849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100795849&partnerID=8YFLogxK
U2 - 10.3390/ijms22041918
DO - 10.3390/ijms22041918
M3 - Article
C2 - 33671956
AN - SCOPUS:85100795849
SN - 1422-0067
VL - 22
SP - 1
EP - 13
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 4
M1 - 1918
ER -